Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Squamous Non-small Cell Lung Cancer × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 22 Carcinoma, Non-Small-Cell Lung 10 Colorectal Neoplasms 8 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Mesothelioma, Malignant 5 Melanoma 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Stomach Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Mesothelioma 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vascular Neoplasms 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1

Interventions

tremelimumab 1 pembrolizumab 1 envafolimab 1 durvalumab 1 Paclitaxel 1 Endostatins 1 Drug Therapy 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03319316 2022-01-10

SOLUTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡